Document is current
Any future updates will be listed below
-
Authors
Cao, Yunlong http://orcid.org/0000-0001-5918-1078
Yisimayi, Ayijiang
Jian, Fanchong http://orcid.org/0000-0001-8703-3507
Song, Weiliang
Xiao, Tianhe
Wang, Lei
Du, Shuo http://orcid.org/0000-0003-0936-0785
Wang, Jing http://orcid.org/0000-0002-9084-9985
Li, Qianqian
Chen, Xiaosu
Yu, Yuanling
Wang, Peng
Zhang, Zhiying http://orcid.org/0000-0002-5690-9796
Liu, Pulan
An, Ran
Hao, Xiaohua
Wang, Yao
Wang, Jing
Feng, Rui
Sun, Haiyan
Zhao, Lijuan
Zhang, Wen
Zhao, Dong
Zheng, Jiang
Yu, Lingling
Li, Can
Zhang, Na
Wang, Rui
Niu, Xiao
Yang, Sijie
Song, Xuetao
Chai, Yangyang
Hu, Ye
Shi, Yansong
Zheng, Linlin
Li, Zhiqiang
Gu, Qingqing
Shao, Fei
Huang, Weijin http://orcid.org/0000-0002-4246-8889
Jin, Ronghua http://orcid.org/0000-0001-8496-172X
Shen, Zhongyang http://orcid.org/0000-0003-0045-4355
Wang, Youchun http://orcid.org/0000-0001-9769-5141
Wang, Xiangxi http://orcid.org/0000-0003-0635-278X
Xiao, Junyu http://orcid.org/0000-0003-1822-1701
Xie, Xiaoliang Sunney http://orcid.org/0000-0001-9281-5239
- License Information
-
More Information
Article History
Received: 30 April 2022
Accepted: 15 June 2022
First Online: 17 June 2022
Competing interests
: X.S.X. and Y. Cao are inventors on the provisional patent applications for BD series antibodies, which includes BD30-604 (DXP-604), BD55-5840 (SA58) and BD55-5514 (SA55). X.S.X. and Y. Cao are founders of Singlomics Biopharmaceuticals. The other authors declare no competing interests.
